Seattle Genetics wins FDA priority review for oral HER2 drug

If approved will compete with AZ/Daiichi Sankyo's Enhertu. Seattle Genetics has scored a US Food and Drug Administration (FDA) priority review for its oral HER2 inhibitor tucatinib in breast ... If Seattle does gain approval for tucatinib, it will go on

20 for 2020 – Five pharma companies to watch

The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... 4. Daiichi Sankyo. The fourth company on our list – Daiichi Sankyo – has something in common with the first.Our

AZ revenues rise, but it says coronavirus could hit 2020

However, the FDA approval of Daiichi Sankyo-partnered HER2 drug Enhertu (trastuzumab deruxtecan) for breast cancer – tipped as a $4.5bn blockbuster by some analysts – came too late to register any

Roche posts minor sales miss in Q4 as biosimilar pressure grows

the latter is facing new competition from AstraZeneca/Daiichi Sankyo’s recently-approved  Enhertu (trastuzumab deruxtecan).

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]